Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
P30876
UPID:
RPB2_HUMAN
Alternative names:
DNA-directed RNA polymerase II 140 kDa polypeptide; DNA-directed RNA polymerase II subunit B; RNA polymerase II subunit 2; RNA polymerase II subunit B2
Alternative UPACC:
P30876; A8K1A8; Q8IZ61
Background:
DNA-directed RNA polymerase II subunit RPB2, also known as DNA-directed RNA polymerase II 140 kDa polypeptide, plays a pivotal role in the transcription of DNA into RNA, utilizing ribonucleoside triphosphates as substrates. It is a crucial component of RNA polymerase II, responsible for synthesizing mRNA precursors and various functional non-coding RNAs. RPB2, alongside the largest subunit, forms the polymerase active center, contributing significantly to the enzyme's catalytic activity.
Therapeutic significance:
Understanding the role of DNA-directed RNA polymerase II subunit RPB2 could open doors to potential therapeutic strategies.